Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 March 2018 Photo Edwin Mthimkhulu
Solomon Mahlangu inspires UFS alumnus first Sesotho book
Ace Moloi questions and delves into the concept of freedomin Tholwana Tsa Tokoloho

Tholwana Tsa Tokoloho is the title of Ace Moloi’s anthology of short stories and the name of one of the 14 stories in the book. The anthology is the first book in Sesotho published by the three-time author.

On Friday, 16 March 2018, Tholwana Tsa Tokoloho, an Art Fusion Literature product, will make its debut public appearance during a public reading at the University of the Free State’s Equitas Auditorium at 17:30.

Moloi’s first literary offering was In Her Fall Rose A Nation which was published in 2013 during his final-year as a Communication Science student at the university. In 2016, Moloi published Holding My Breath, which was praised widely for stirring emotions in readers who related to the heart-wrenching narrative of losing a mother. It was only this year that the author managed to achieve his teenage goal of establishing himself as a vernacular author.

Solomon Mahlangu, an African National Congress freedom fighter and Umkhonto we Sizwe militant who was convicted of murder and hanged in 1979, was the inspiration behind the anthology. Mahlangu inspired the Tholwana Tsa Tokoloho story, which is the story of the selflessness of a captured guerrilla hero in the face of police torture and his eventual death by hanging. It represents Mahlangu and those who suffered during the struggle for liberation. 

“My blood will nourish the tree that will bear the fruits of freedom,” are the supposed last words uttered by Mahlangu that inspired the book’s title. Tholwana Tsa Tokoloho means “the fruits of freedom” in Sesotho. For Moloi, writing in the vernacular symbolises the fruits of freedom. “I’m trying to write in a revolutionary spirit, in Sesotho, because we haven’t done that. We have not seriously interrogated political concepts in Sesotho or in any native language,” he said.

Graduate unemployment, violent crime, and sports are some of the other topics tackled in the book. These act as a catalyst for debates over the evidence of ‘the fruits of freedom’ in post-1994 South Africa. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept